altiratinib
Small moleculeexperimental
Clinical trial activity
1 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Jun 1, 2014 (NCT02228811)
Timeline
2010s
- Jan 1, 2014
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
Mechanism of action
KDR inhibitor
- Tyrosine-protein kinase TIE-2INHIBITOR
TEK inhibitor
- Hepatocyte growth factor receptorINHIBITOR
MET inhibitor
Neurotrophic tyrosine kinase receptor inhibitor
Chemistry & pharmacology
Loading structure…
SMILES
O=C(Nc1cc(Oc2cc(F)c(NC(=O)C3(C(=O)Nc4ccc(F)cc4)CC3)cc2F)ccn1)C1CC1- Mol. weight
- 510.47 g/mol
- Lipinski Ro5
- 1 violation(s)
- Rule of 3
- No
- Chirality
- Achiral Molecule
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL3545365 ↗
Also known as
- altiratinib
- altiratinib
- dcc-2701
- dcc-2701
- dcc-2701
- dp-5164
- dp-5164
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT02228811 | Phase 1 | Jun 1, 2014 | Deciphera Pharmaceuticals LLC |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Deciphera Pharmaceuticals LLC | For profit | 1 | 1 | 1 | 2014 |
1 organizations
Page 1 / 1